Literature DB >> 34007692

Impact of Pharmacist-Led Diabetes Management in Primary Care Clinics.

Benjamin A Pontefract1, Benjamin S King1, David M Gothard2, Cynthia A King1,3.   

Abstract

PURPOSE: Current literature supports pharmacists effectively lower hemoglobin A1c (HbA1c) in diabetic patients. Little data exists on pharmacists' effects on comorbidity management, patient satisfaction, or the financial viability of these positions. This study looked to assess the impact of pharmacists on diabetes management compared to usual care.
METHODS: This multi-site, two-part study includes a retrospective chart review of patients referred to the pharmacist versus usual care within a large academic health system. The pharmacists collaborated under a consult agreement with primary care physicians. The second part of the study assessed patient satisfaction through an abbreviated CG-CAHPS survey.
RESULTS: A total of 206 patients with diabetes for an average of 12 years were included. The average patient age was 62 years with 60% of patients identifying as female and 81% as African-American. Patients were enrolled in a 2:1 fashion with 138 patients in the pharmacist-management group. Average baseline HbA1c was 10.1% in the pharmacist-management group and 9.3% in the usual care group (p= 0.0125). At 6 months, the mean change in HbA1c was -2.17% and 0.48% for the intervention and control groups respectively (p < 0.001).
CONCLUSION: Pharmacists are effective at lowering HbA1c in primary care clinics, and patients were highly satisfied with these services. While direct revenue from this service did not meet cost, the pharmacist did positively affect outcomes that contribute to reimbursement. © University of Minnesota Libraries Publishing.

Entities:  

Keywords:  HbA1c; ambulatory; diabetes; pharmacist; revenue; satisfaction

Year:  2018        PMID: 34007692      PMCID: PMC6438548          DOI: 10.24926/iip.v9i2.985

Source DB:  PubMed          Journal:  Innov Pharm        ISSN: 2155-0417


  7 in total

1.  Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial.

Authors:  Hae Mi Choe; Sonya Mitrovich; Daniel Dubay; Rodney A Hayward; Sarah L Krein; Sandeep Vijan
Journal:  Am J Manag Care       Date:  2005-04       Impact factor: 2.229

2.  The cost to health plans of poor glycemic control.

Authors:  T P Gilmer; P J O'Connor; W G Manning; W A Rush
Journal:  Diabetes Care       Date:  1997-12       Impact factor: 19.112

3.  Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.

Authors:  Elizabeth Selvin; Spyridon Marinopoulos; Gail Berkenblit; Tejal Rami; Frederick L Brancati; Neil R Powe; Sherita Hill Golden
Journal:  Ann Intern Med       Date:  2004-09-21       Impact factor: 25.391

4.  Impact of a pharmacist led diabetes mellitus intervention on HbA1c, medication adherence and quality of life: A randomised controlled study.

Authors:  Mubashra Butt; Adliah Mhd Ali; Mohd Makmor Bakry; Norlaila Mustafa
Journal:  Saudi Pharm J       Date:  2015-03-06       Impact factor: 4.330

5.  Economic Costs of Diabetes in the U.S. in 2017.

Authors: 
Journal:  Diabetes Care       Date:  2018-03-22       Impact factor: 19.112

6.  Projecting the future diabetes population size and related costs for the U.S.

Authors:  Elbert S Huang; Anirban Basu; Michael O'Grady; James C Capretta
Journal:  Diabetes Care       Date:  2009-12       Impact factor: 19.112

7.  Economic costs of diabetes in the U.S. in 2012.

Authors: 
Journal:  Diabetes Care       Date:  2013-03-06       Impact factor: 19.112

  7 in total
  1 in total

Review 1.  Pharmacist-Managed Diabetes Programs: Improving Treatment Adherence and Patient Outcomes.

Authors:  Amanda Wojtusik Orabone; Vincent Do; Elizabeth Cohen
Journal:  Diabetes Metab Syndr Obes       Date:  2022-06-20       Impact factor: 3.249

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.